Full Press Release Details
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Morgan Stanley 23rdAnnual Global Healthcare Conference on Monday, September 8, 2025, at 10:45 a.m. E.T. in New York, NY.
A live webcast of the Company presentation will be available through the investor relations section of the Company's website atwww.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.
About Akero TherapeuticsAkero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONYHistologyin patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONYOutcomesin patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONYReal-Worldin patients with MASH or MASLD (metabolic dysfunction associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us atakerotx.comand follow us onLinkedInandXfor more information.